Executive summary

Disclosed time savings from live cases in Japan
% less time or distance than before · owner-disclosed · 2023-2026
Hit to drug candidate ~70% Clinical study report drafting 35% Trial patient selection ~33% (projected) Trial statistical programming 30% Warehouse picker travel 22.6% (trial)
Source: [Astellas 2024]; [MHLW grant 2025]; [Fujitsu 2025]; [Shionogi 2023]; [Medipal 2023]

Three reasons

Labour, not cost, drives the case. Medical representatives fell 6.6% in a year to 43,646 [MR Center 2025], and pharmacists record guidance for 896 mn prescriptions a year [MHLW 2025 dispensing].

Document work already shows results. A cancer centre cut report drafting from 120 to 78 working days [MHLW grant 2025]; Shionogi cut trial programming hours by 30% [Shionogi 2023].

Discovery and patient data stall. Chugai dropped its only clinical antibody designed with its own model [Fierce 2026], and only 19.4% of hospitals issue e-prescriptions [Digital Agency 2026].

AnswerConditional go, as a supplier through a Japanese partner: document, record and sales-support tools pay back in one to two years; discovery and patient-facing tools are three-to-five-year bets [Kira estimates].
Sell time back to clinical, pharmacy and sales teams first; treat discovery and patient-facing software as options, not the entry.
Astellas 2024 · Digital Agency 2026 · Fierce 2026 · Fujitsu 2025 · Medipal 2023 · MHLW 2025 dispensing · MHLW grant 2025 · MR Center 2025 · Shionogi 2023 · Kira estimates · full citations in the source index

Clinical documents, safety writing, pharmacy records and MR work carry most of the exposure; plants and pricing carry the least

Exposure here means work that is rule-based and repeated at volume, not where models make the most headlines.

Where the segment is exposed
Score 0-5 · x = share of work that is documents, rules and pattern checks · y = staff time and volume · bubble = cost weight
Exposed now Volume, little to automate Low priority Rule-heavy, small 0 0 1 1 2 2 3 3 4 4 5 5 Share of work that is documents and rules (0-5) Staff time and volume (0-5) Clinical documents and data Regulatory and safety writing Pharmacy records and follow-up MR and medical work Supply planning and wholesale Discovery research Manufacturing and quality Market access and pricing
Source: [Kira estimates] from process volumes on the following pages

Why writing work leads

Volumes are large. Pharmacies dispensed 896 mn prescriptions in FY2024, each with a written guidance record [MHLW 2025 dispensing].

Documents are slow and outsourced. An outsourced clinical study report takes over six months and costs JPY 5 mn or more [MHLW grant 2025].

Labs are different. Discovery is exposed to models, but the work is experiments; the gain is speed, which is harder to bank than hours.

NoteScores are our judgement on disclosed process volumes, not measured time studies.
Map the offer to the four top-right areas; do not lead with plant or pricing automation.
MHLW 2025 dispensing = MHLW dispensing costs FY2024 · MHLW grant 2025 = MHLW research grant report, FY2025 · Kira estimates = KIRA analyst triangulation